Oxidative stress in autoimmune joint diseases
Investigation of the Role of Redox Status of Patients With Autoimmune Rheumatic Diseases on Disease Progression: An Epidemiological Study
Researchers will see if oxidative stress and antioxidant markers differ in adults with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Thessaly Academic / other |
| Locations | 1 site (Larissa, Thessaly) |
| Trial ID | NCT07536529 on ClinicalTrials.gov |
What this trial studies
This observational project will enroll adults with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis at the General University Hospital of Larissa. Biological samples (such as blood) and clinical information on disease status, treatments, comorbidities, diet and physical activity will be collected. Laboratory assays will measure oxidative stress and antioxidant markers and statistical analyses will look for patterns and correlations with disease type, severity, comorbidity and therapy. No experimental treatments are given; the work aims to deepen understanding of molecular changes associated with these conditions.
Who should consider this trial
Good fit: Adults aged 18 or older with a confirmed primary diagnosis of rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis are eligible regardless of disease duration, status, comorbidities, or current treatments.
Not a fit: People under 18, those with non-autoimmune joint conditions, or patients unable to attend hospital visits are unlikely to benefit from or be eligible for this work.
Why it matters
Potential benefit: If successful, the findings could reveal oxidative stress patterns that inform personalized supportive therapies or lifestyle recommendations to reduce complications.
How similar studies have performed: Previous observational studies have reported altered oxidative stress markers in rheumatoid and psoriatic arthritis, so this work builds on existing evidence rather than testing an entirely novel concept.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (\>18 years old), with a primary diagnosis of rheumatoid arthritis using the criteria of American College of Rheumatology (ACR) * Adult patients (\>18 years old), with a primary diagnosis of psoriatic arthritis using the ClASsification criteria for Psoriatic Arthritis (CASPAR) * Adult patients (\>18 years old), with a primary diagnosis of alkylosing spondyloarthritis using the criteria of Assessment of SpondyloArthritis international Society (ASAS) group * Adult patients (\>18 years old) irrespective of gender * Adult patients (\>18 years old) irrespective of ethnicity * Adult patients (\>18 years old) irrespective of comorbidities * Adult patients (\>18 years old) irrespective of socioeconomic background * Adult patients (\>18 years old) with any disease status * Adult patients (\>18 years old) with any disease duration * Adult patients (\>18 years old) under any treatment scheme (e.g. non-steroidal anti-inflammatory drugs, steroids, disease-modifying anti-rheumatic drugs including biologics) Exclusion Criteria: * Adult patients (\>18 years old) with concurrent infectious disease * Adult patients (\>18 years old) in pregnancy * Patients under 18 years of age
Where this trial is running
Larissa, Thessaly
- General University Hospital of Larissa. Greece — Larissa, Thessaly, Greece (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.